Your shopping cart is currently empty

L-838417 is a GABAA receptor subtype-selective benzodiazepine site-selective ligand and GABAA receptor-positive modulator.L-838417 is a selective partial agonist of the α2, α3, and α5 subtypes and an antagonist of the α1 subtype and is used in the study of anxiety disorders.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $48 | In Stock | In Stock | |
| 5 mg | $196 | In Stock | In Stock | |
| 10 mg | $227 | In Stock | In Stock | |
| 25 mg | $548 | In Stock | In Stock | |
| 50 mg | $828 | In Stock | In Stock | |
| 100 mg | $1,230 | In Stock | In Stock |
| Description | L-838417 is a GABAA receptor subtype-selective benzodiazepine site-selective ligand and GABAA receptor-positive modulator.L-838417 is a selective partial agonist of the α2, α3, and α5 subtypes and an antagonist of the α1 subtype and is used in the study of anxiety disorders. |
| Targets&IC50 | α5β3γ2:2.25 nM (Ki), α1β3γ2:0.79 nM (Ki), α4β3γ2:267 nM (Ki), α2β3γ2:0.67 nM (Ki), α6β3γ2:2183 nM (Ki), α3β3γ2:1.67 nM (Ki) |
| In vivo | In unfamiliar environments, adult rats: at a dose of 1.0 mg/kg L-838417, social avoidance shifted to social preference and increased social probing. Adolescent rats: at 2.0 mg/kg L-838417 dose, elimination of social avoidance but no increase in social probing. [2] In familiar environments (after repeated restraint stress), reversal of stress-induced anxiety effects, regardless of age, at 0.5 mg/kg L-838417 dose. ≥1.0 mg/kg L-838417 dose, reduced social probing, possibly related to inhibition of motor function. [2] |
| Synonyms | L838417, L 838417 |
| Molecular Weight | 399.4 |
| Formula | C19H19F2N7O |
| Cas No. | 286456-42-6 |
| Smiles | FC=1C=CC(F)=C(C1)C2=NN=C3C=C(C(=NN32)OCC4=NC=NN4C)C(C)(C)C |
| Relative Density. | 1.40 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (50.08 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 2 mg/mL (5.01 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.